Recurrent Pterygium Clinical Trial
Official title:
Intraoperative Mitomycin C Combined With Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium: a Randomized Clinical Trial
The purpose of this randomized clinical trial is to compare the efficacy and safety of intraoperative mitomycin C(MMC) combined with limbal conjunctival autograft(LCAG) or conjunctival autograft(CAG) for recurrent pterygium surgery. The investigators will also evaluate particular risk factors related to pterygium recurrence
Intraoperative mitomycin C after pterygium excision is widely used to prevent recurrce of
recurrent pterygium. Conjunctival autograft with or without limbal tissue used to cover the
bare sclera will efficiently reduce postoperative longstanding epithelial defect.
Patients with recurrent pterygium will be randomly assigned to undertake pterygium excision
followed by intraoperative mitomycin C with conjunctival autograft or limbal conjunctival
autograft .The patients will be followed at least 12 months. Corneal recurrence is considered
as a fibrovascular ingrowth beyond the limbus with conjunctival drag in the area of previous
pterygium excision.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02486484 -
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
|
Phase 2 | |
Completed |
NCT02007174 -
Bevacizumab Injection for Recurrent Pterygium
|
N/A | |
Completed |
NCT05362253 -
Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial
|
N/A | |
Active, not recruiting |
NCT02530801 -
Strategies for Management of Recurrent Pterygium
|
Phase 4 | |
Completed |
NCT01744756 -
Subconjunctival Bevacizumab and Recurrent Pterygium
|
Phase 2/Phase 3 | |
Completed |
NCT02059837 -
Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery
|
N/A | |
Completed |
NCT01319721 -
Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
|
N/A |